<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: fluctuations", fill: "#483c32"},
{source: "4: fluctuations", target: "4: acquisitions", fill: "#483c32"},
{source: "4: acquisitions", target: "4: significant customer orders", fill: "#483c32"},
{source: "4: significant customer orders", target: "4: market acceptance", fill: "#483c32"},
{source: "4: market acceptance", target: "4: existing products as well as products", fill: "#483c32"},
{source: "4: existing products as well as products", target: "4: development", fill: "#483c32"},
{source: "4: development", target: "4: regulatory approvals", fill: "#483c32"},
{source: "4: regulatory approvals", target: "4: exchange between", fill: "#483c32"},
{source: "4: exchange between", target: "4: foreign countries", fill: "#483c32"},
{source: "4: foreign countries", target: "4: expenses incurred", fill: "#483c32"},
{source: "4: expenses incurred", target: "4: connection with product field", fill: "#483c32"},
{source: "4: connection with product field", target: "4: corrections", fill: "#483c32"},
{source: "4: corrections", target: "4: manufacture", fill: "#483c32"},
{source: "4: manufacture", target: "4: products efficiently", fill: "#483c32"},
{source: "4: products efficiently", target: "4: development expenditures", fill: "#483c32"},
{source: "4: fluctuations", target: "8: Competition ", fill: "#eee600"},
{source: "8: Competition ", target: "8: also comes from early stage companies", fill: "#eee600"},
{source: "8: also comes from early stage companies", target: "8: alternative technological solutions", fill: "#eee600"},
{source: "8: alternative technological solutions", target: "8: primary clinical targets as", fill: "#eee600"},
{source: "8: primary clinical targets as", target: "8: well as universities research institutions", fill: "#eee600"},
{source: "8: well as universities research institutions", target: "8: nonprofit entities", fill: "#eee600"},
{source: "8: Competition ", target: "9: competitors", fill: "#fae7b5"},
{source: "9: competitors", target: "9: development", fill: "#fae7b5"},
{source: "9: development", target: "9: manufacturing", fill: "#fae7b5"},
{source: "9: manufacturing", target: "9: distribution", fill: "#fae7b5"},
{source: "9: distribution", target: "9: resources than", fill: "#fae7b5"},
{source: "9: competitors", target: "10: competitors may", fill: "#20b2aa"},
{source: "10: competitors may", target: "10: effective at implementing", fill: "#20b2aa"},
{source: "10: effective at implementing", target: "10: technologies", fill: "#20b2aa"},
{source: "10: technologies", target: "10: commercial products", fill: "#20b2aa"},
{source: "10: competitors may", target: "16: Competitive ", fill: "#eae0c8"},
{source: "16: Competitive ", target: "16: could adversely affect", fill: "#eae0c8"},
{source: "16: could adversely affect", target: "16: profitability", fill: "#eae0c8"},
{source: "16: Competitive ", target: "42: development activities", fill: "#00416a"},
{source: "42: development activities", target: "42: manufacturing labeling", fill: "#00416a"},
{source: "42: manufacturing labeling", target: "42: distribution", fill: "#00416a"},
{source: "42: distribution", target: "42: future products", fill: "#00416a"},
{source: "42: future products", target: "42: regulation by numerous governmental agencies", fill: "#00416a"},
{source: "42: regulation by numerous governmental agencies", target: "42: United States ", fill: "#00416a"},
{source: "42: development activities", target: "61: regulations", fill: "#d99058"},
{source: "61: regulations", target: "63: regulations", fill: "#00bfff"},
{source: "63: regulations", target: "63: requirements", fill: "#00bfff"},
{source: "63: requirements", target: "63: medical devices", fill: "#00bfff"},
{source: "63: medical devices", target: "63: requirements governing", fill: "#00bfff"},
{source: "63: requirements governing", target: "63: clinical trials", fill: "#00bfff"},
{source: "63: clinical trials", target: "63: manufacturing", fill: "#00bfff"},
{source: "63: manufacturing", target: "63: distribution", fill: "#00bfff"},
{source: "63: regulations", target: "139: manufacture", fill: "#fb9902"},
{source: "139: manufacture", target: "139: facilities", fill: "#fb9902"},
{source: "139: manufacture", target: "START_HERE", fill: "#fb9902"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_analysis">Profitability analysis</a></td>
      <td>In cost accounting, profitability analysis is an analysis of the profitability of an organisation's output. Output of an organisation can be grouped into products, customers, locations, channels and/or transactions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_index">Profitability index</a></td>
      <td>Profitability index (PI), also known as profit investment ratio (PIR) and value investment ratio (VIR), is the ratio of payoff to investment of a proposed project. It is a useful tool for ranking projects because it allows you to quantify the amount of value created per unit of investment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Small_Is_Profitable">Small Is Profitable</a></td>
      <td>Small Is Profitable: The Hidden Economic Benefits of Making Electrical Resources the Right Size is a 2002 book by energy analyst Amory Lovins and others.  The book describes 207 ways in which the size of "electrical resources"—devices that make, save, or store electricity—affects their economic value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SAP_ERP">SAP ERP</a></td>
      <td>SAP ERP is an enterprise resource planning software developed by the German company SAP SE. SAP ERP incorporates the key business functions of an organization. The latest version of SAP ERP (V.6.0) was made available in 2006.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Net_income">Net income</a></td>
      <td>In business and accounting, net income (also total comprehensive income, net earnings, net profit, bottom line, sales profit, or credit sales) is an entity's income minus cost of goods sold, expenses, depreciation and amortization, interest, and taxes for an accounting period.It is computed as the residual of all revenues and gains less all expenses and losses for the period, and has also been defined as the net increase in shareholders' equity that results from a company's operations. It is different from gross income, which only deducts the cost of goods sold from revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/History_of_the_United_States">History of the United States</a></td>
      <td>The history of the lands that became the United States began with the arrival of the first people in the Americas around 15,000 BC. Numerous indigenous cultures formed, and many saw transformations in the 16th century away from more densely populated lifestyles and towards reorganized polities elsewhere.  The European colonization of the Americas began in the late 15th century, however most colonies in what would later become the United States were settled after 1600.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_Devices_Directive">Medical Devices Directive</a></td>
      <td>The Medical Device Directive (Council Directive 93/42/EEC of 14 June 1993  concerning medical devices, OJ No L 169/1 of 1993-07-12) is intended to harmonise the laws relating to medical devices within the European Union. The MD Directive is a 'New Approach' Directive and consequently in order for a manufacturer to legally place a medical device on the European market the requirements of the MD Directive have to be met.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_device_regulation">Medical device regulation</a></td>
      <td>A medical device is any device intended to be used for medical purposes. Significant potential for hazards are inherent when using a device for medical purposes and thus medical devices must be proved safe and effective with reasonable assurance before regulating governments allow marketing of the device in their country.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biomedical_engineering">Biomedical engineering</a></td>
      <td>Biomedical engineering (BME) or medical engineering is the application of engineering principles and design concepts to medicine and biology for healthcare purposes (e.g., diagnostic or therapeutic). BME is also traditionally known as "bioengineering", but this term has come to also refer to biological engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medical_Devices_Park,_Hyderabad">Medical Devices Park, Hyderabad</a></td>
      <td>Medical Devices Park, Hyderabad is a medical devices industrial estate located in Hyderabad, Telangana, India. The largest such Park in India spread over 250 acres.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Abbott_Laboratories">Abbott Laboratories</a></td>
      <td>Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Zubieta_Facilities">Zubieta Facilities</a></td>
      <td>The Zubieta Facilities (Basque: Zubietako Kirol-instalakuntzak, Spanish: Instalaciones de Zubieta), is the training ground of the Primera Division club Real Sociedad. Located in Zubieta, an enclave of San Sebastian (adjacent to the San Sebastián Hippodrome), it was opened in 2004 in its modernised form, although was originally inaugurated in 1981.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Facilities_Society">The Facilities Society</a></td>
      <td>The Facilities Society was founded in the UK on 9 December 2008 as a not-for-profit company limited by guarantee (registered in England nr. 6769050).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Our operating results, including <font color="blue">components</font> of operating results, such as gross  margin on product sales, may <font color="blue">fluctuate from</font> time to time, and <font color="blue">such <font color="blue">fluctuations</font></font>  <font color="blue">could affect</font> our stock price</td>
    </tr>
    <tr>
      <td>Our operating results have fluctuated in the past  and can be expected to <font color="blue">fluctuate from</font> time to time in the future</td>
    </tr>
    <tr>
      <td>Some of the  factors that may cause these <font color="blue">fluctuations</font> include:          o  the impact of <font color="blue"><font color="blue">acquisition</font>s</font>;        o  the timing of <font color="blue"><font color="blue">significant</font> customer orders</font>;        o  <font color="blue">market <font color="blue">acceptance</font></font> of our <font color="blue">existing products</font>, as well as products in           <font color="blue">development</font>;        o  the timing of <font color="blue"><font color="blue">regulatory</font> approvals</font>;        o  changes in the rate of <font color="blue">exchange between</font> the US dollar and other           currencies of <font color="blue">foreign countries</font> in which we do business, such as the           euro and the British pound;        o  <font color="blue">expenses incurred</font> and business lost in <font color="blue">connection with product field</font>           <font color="blue">corrections</font> or recalls;        o  increases in the cost of energy and steel;        o  our ability to <font color="blue">manufacture</font> our <font color="blue">products efficiently</font>; and        o  the timing of our research and <font color="blue">development</font> expenditures</td>
    </tr>
    <tr>
      <td>In general, there is <font color="blue">intense <font color="blue">competition</font> among medical</font> device companies</td>
    </tr>
    <tr>
      <td>We  <font color="blue">compete with established medical <font color="blue">technology</font></font> and <font color="blue">pharmaceutical companies</font> in many  of our <font color="blue">product areas</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font><font color="blue">also comes from early stage companies</font> that  have <font color="blue"><font color="blue">alternative</font> technological solutions</font> for our primary clinical targets, as  well as universities, research institutions and other non-profit entities</td>
    </tr>
    <tr>
      <td>Many  of our <font color="blue">competitors</font> have access to greater financial, technical, research and  <font color="blue">development</font>, marketing, <font color="blue">manufacturing</font>, sales, <font color="blue">distribution</font> services and other  <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may be more <font color="blue"><font color="blue">effective</font> at implementing</font>  their <font color="blue">technologies</font> to develop <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may be able  to <font color="blue">gain market</font> share by offering lower-cost products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitive</font> position will depend on</font> our ability to achieve <font color="blue">market <font color="blue">acceptance</font></font>  for our products, develop <font color="blue">new products</font>, implement production and marketing  plans, <font color="blue">secure <font color="blue">regulatory</font> approval</font> for products under <font color="blue">development</font>, obtain  <font color="blue"><font color="blue">reimbursement</font> under</font> Medicare and obtain patent protection</td>
    </tr>
    <tr>
      <td>We may need to  develop <font color="blue">new <font color="blue">application</font>s</font> for our products to <font color="blue">remain <font color="blue">competitive</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Technological  </font><font color="blue">advances by one</font> or more of our current or future <font color="blue">competitors</font> could render our  present or <font color="blue"><font color="blue">future products</font> obsolete</font> or uneconomical</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will</font>  <font color="blue">depend upon</font> our ability to <font color="blue">compete <font color="blue"><font color="blue">effective</font>ly</font> against current <font color="blue">technology</font> as</font>  well as to respond <font color="blue"><font color="blue">effective</font>ly</font> to <font color="blue">technological advances</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitive </font>pressures  <font color="blue">could <font color="blue">adversely affect</font></font> our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>For example, two of our largest  <font color="blue">competitors</font> introduced an onlay dural graft matrix during 2004, and other  companies have introduced and may be preparing to introduce similar products</td>
    </tr>
    <tr>
      <td>The introduction of <font color="blue">such <font color="blue">products could</font> reduce</font> the sales, growth in sales and  <font color="blue">profitability</font> of our <font color="blue">duraplasty</font> products</td>
    </tr>
    <tr>
      <td>Our largest <font color="blue">competitors</font> in the <font color="blue">neurosurgery markets</font> are the Medtronic  Neurosurgery division of Medtronic, Inc, the Codman division of Johnson &amp;  Johnson, the Aesculap division of <font color="blue">B Braun Medical Inc</font></td>
    </tr>
    <tr>
      <td>and the <font color="blue">Valleylab  </font>division of <font color="blue">Tyco International Ltd</font></td>
    </tr>
    <tr>
      <td>In addition, many of our <font color="blue">product lines</font>  <font color="blue">compete with smaller specialized companies</font> or <font color="blue">larger companies</font> that do not  <font color="blue">otherwise focus on neurosurgery</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> in <font color="blue"><font color="blue">reconstructive</font> surgery</font>  include LifeCell Corporation, Organogenesis Inc, Wright Medical Group, Inc,  the DePuy division of Johnson &amp; Johnson, Synthes, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">Stryker Corporation</font></td>
    </tr>
    <tr>
      <td>Some of these are major orthopedic companies that carry a full line of  <font color="blue">reconstructive</font> products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue"><font color="blue">private label</font> products</font> face diverse</font> and broad  <font color="blue">competition</font>, depending on the market that an individual <font color="blue">product addresses</font></td>
    </tr>
    <tr>
      <td>11  <PAGE>    Finally, in certain cases our products compete primarily against medical  practices that treat a condition without using a device, rather than any  particular product, such as <font color="blue">autograft tissue</font> as an <font color="blue">alternative</font> for our dermal  <font color="blue">regeneration</font> products, our <font color="blue">duraplasty</font> products and our nerve repair products</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">internal growth</font>, our <font color="blue">current strategy involves growth through</font>  <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>Since 1999, we have acquired 22 <font color="blue">businesses</font> or <font color="blue">product lines</font> at a  <font color="blue">total cost</font> of approximately dlra289 million</td>
    </tr>
    <tr>
      <td>We may be unable to continue to implement our <font color="blue">growth strategy</font>, and our strategy  <font color="blue">ultimately may</font> be <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our growth in revenues  has resulted from, and is expected to continue to result from, the <font color="blue">acquisition</font>  of <font color="blue"><font color="blue">businesses</font> complementary</font> to our own</td>
    </tr>
    <tr>
      <td>We engage in <font color="blue">evaluations</font> of potential  <font color="blue"><font color="blue">acquisition</font>s</font> and are in <font color="blue">various stages</font> of discussion regarding possible  <font color="blue"><font color="blue">acquisition</font>s</font>, certain of which, if consummated, could be <font color="blue">significant</font> to us</td>
    </tr>
    <tr>
      <td>Any  potential <font color="blue"><font color="blue">acquisition</font>s</font> may result in material transaction expenses, increased  interest and amortization expense, increased depreciation expense and increased  operating expense, any of <font color="blue">which could</font> have a material adverse effect on our  operating results</td>
    </tr>
    <tr>
      <td>As we grow by <font color="blue"><font color="blue">acquisition</font>s</font>, we <font color="blue">must integrate</font> and manage the  <font color="blue">new <font color="blue">businesses</font></font> to realize economies of scale and <font color="blue">control costs</font></td>
    </tr>
    <tr>
      <td>In addition,  <font color="blue"><font color="blue">acquisition</font>s</font> involve other risks, including diversion of <font color="blue"><font color="blue">management</font> resources</font>  <font color="blue">otherwise available</font> for ongoing <font color="blue">development</font> of our business and <font color="blue">risks associated</font>  <font color="blue">with entering new markets with which</font> our marketing and <font color="blue">sales force</font> has limited  experience or where experienced <font color="blue">distribution</font> alliances are not available</td>
    </tr>
    <tr>
      <td>Our  future <font color="blue">profitability</font> will depend in part upon our ability to develop further our  resources to adapt to these <font color="blue">new products</font> or business areas and to identify and  <font color="blue">enter into</font> satisfactory <font color="blue">distribution</font> networks</td>
    </tr>
    <tr>
      <td>We may not be able to identify  suitable <font color="blue">acquisition</font> candidates in the future, obtain acceptable financing or  consummate any future <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot integrate</font> acquired <font color="blue">operations</font>,  manage the cost of providing our products or price our <font color="blue">products <font color="blue">appropriate</font>ly</font>,  our <font color="blue">profitability</font> could suffer</td>
    </tr>
    <tr>
      <td>In addition, as a result of our <font color="blue"><font color="blue">acquisition</font>s</font> of  other <font color="blue">healthcare <font color="blue">businesses</font></font>, we may be subject to the risk of <font color="blue">unanticipated</font>  business <font color="blue">uncertainties</font>, <font color="blue">regulatory</font> matters or <font color="blue">legal liabilities</font> relating to  those acquired <font color="blue">businesses</font> for which the sellers of the acquired <font color="blue">businesses</font> may  not <font color="blue">indemnify us</font></td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> activities and the <font color="blue">manufacturing</font>, labeling,  <font color="blue">distribution</font> and marketing of our existing and <font color="blue">future products</font> are subject to  <font color="blue">regulation by numerous <font color="blue">government</font>al agencies</font> in the <font color="blue"><font color="blue">United States</font> </font>and in other  countries</td>
    </tr>
    <tr>
      <td>The Food and Drug Administration (FDA) and comparable agencies in  other countries impose <font color="blue">mandatory</font> procedures and standards for the conduct of  <font color="blue">clinical trials</font> and the production and marketing of products for <font color="blue">diagnostic</font> and  <font color="blue">human therapeutic use</font></td>
    </tr>
    <tr>
      <td>Our products under <font color="blue">development</font> are subject to FDA approval or <font color="blue">clearance prior</font> to  marketing for <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue">necessary</font> FDA approvals  or <font color="blue">clearances</font> can take years and is expensive and full of <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">inability</font> to obtain required <font color="blue"><font color="blue">regulatory</font> approval on</font> a timely or acceptable basis  <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>Further, approval or <font color="blue">clearance may</font> place substantial  <font color="blue">restrictions on</font> the <font color="blue">indications</font> for which the product may be marketed or to whom  it may be marketed, the warnings that may be required to <font color="blue">accompany</font> the product  or <font color="blue"><font color="blue">additional</font> restrictions placed on</font> the sale and/or use of the product</td>
    </tr>
    <tr>
      <td><font color="blue">Further  </font>studies, including <font color="blue">clinical trials</font> and FDA approvals, may be required to gain  approval for the use of a product for clinical <font color="blue">indications</font> other than those for  which the product was <font color="blue">initially approved</font> or cleared or for <font color="blue">significant</font> changes  to the product</td>
    </tr>
    <tr>
      <td>In addition, for <font color="blue">products with</font> an approved Pre-Marketing  Approval (PMA), the FDA requires annual reports and may require post-approval  <font color="blue">surveillance programs</font> to monitor the products &amp;apos  safety and <font color="blue"><font color="blue">effective</font>ness</font></td>
    </tr>
    <tr>
      <td><font color="blue">Results  </font>of post-approval programs may limit or expand the further marketing of the  product</td>
    </tr>
    <tr>
      <td>Another risk of <font color="blue">application</font> to the FDA relates to the <font color="blue">regulatory</font> classification  of <font color="blue">new products</font> or <font color="blue">proposed new uses</font> for <font color="blue">existing products</font></td>
    </tr>
    <tr>
      <td>In the filing of  each <font color="blue">application</font>, we make a legal judgment about the <font color="blue">appropriate</font> form and  content of the <font color="blue">application</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font><font color="blue">disagrees with</font> our judgment in any  <font color="blue">particular case</font> and, for example, requires us to file a PMA <font color="blue">application</font> rather  <font color="blue">than allowing us</font> to market for <font color="blue">approved uses while</font> we <font color="blue">seek broader approvals</font> or  requires extensive <font color="blue"><font color="blue">additional</font> clinical data</font>, the time and expense required to  obtain the required <font color="blue">approval might</font> be <font color="blue">significant</font>ly increased or <font color="blue">approval might</font>  not be granted</td>
    </tr>
    <tr>
      <td>12  <PAGE>      Approved products are subject to continuing FDA <font color="blue">requirements</font> relating to quality  control and quality assurance, maintenance of records, reporting of adverse  events and product recalls, <font color="blue">documentation</font>, and labeling and promotion of medical  devices</td>
    </tr>
    <tr>
      <td>The FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> require that our products be  <font color="blue">manufacture</font>d <font color="blue">according</font> to rigorous standards</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulatory</font> <font color="blue">requirements</font> may  <font color="blue">significant</font>ly increase our production or <font color="blue">purchasing costs</font> and <font color="blue">may even prevent</font>  us from making or obtaining our products in <font color="blue">amounts sufficient</font> to <font color="blue">meet market</font>  demand</td>
    </tr>
    <tr>
      <td>If we or a third-party <font color="blue">manufacture</font>r change our approved <font color="blue">manufacturing</font>  process, the FDA may require a <font color="blue">new approval</font> before that <font color="blue">process may</font> be used</td>
    </tr>
    <tr>
      <td>Failure to develop our <font color="blue">manufacturing</font> <font color="blue">capability</font> may mean that even if we develop  promising <font color="blue">new products</font>, we may not be able to produce them profitably, as a  result of delays and <font color="blue">additional</font> capital <font color="blue">investment</font> costs</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing  </font><font color="blue">facilities</font>, both <font color="blue">international</font> and domestic, are also subject to <font color="blue">inspections by</font>  or under the authority of the FDA In addition, failure to <font color="blue">comply with</font>  applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> could subject us to <font color="blue">enforcement action</font>,  including product seizures, recalls, withdrawal of <font color="blue">clearances</font> or approvals,  <font color="blue">restrictions on</font> or <font color="blue">injunctions against marketing</font> our product or <font color="blue">products based</font>  on our <font color="blue">technology</font>, cessation of <font color="blue">operations</font> and civil and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>We are also subject to the <font color="blue">regulatory</font> <font color="blue">requirements</font> of <font color="blue">countries outside</font> of the  <font color="blue"><font color="blue">United States</font> </font>where we do business</td>
    </tr>
    <tr>
      <td>For example, Japan is in the process of  reforming its medical device <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">recent <font color="blue">amendment</font></font> to Japanapstas  Pharmaceutical Affairs Law went into effect on April 1, 2005</td>
    </tr>
    <tr>
      <td>New <font color="blue">regulations</font>  and <font color="blue">requirements</font> exist for obtaining approval of <font color="blue">medical devices</font>, including new  <font color="blue">requirements</font> governing the conduct of <font color="blue">clinical trials</font>, the <font color="blue">manufacturing</font> of  products and the <font color="blue">distribution</font> of products in Japan</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">resources also</font>  may be needed to <font color="blue">comply with</font> the extensive auditing of and requests for  <font color="blue">documentation</font> relating to all <font color="blue">manufacturing</font> <font color="blue">facilities</font> of our company and our  <font color="blue">vendors by</font> the Ministry of Health, Labor and Welfare in Japan to <font color="blue">comply with</font> the  <font color="blue">amendment</font> <font color="blue">to the Pharmaceutical Affairs Law</font></td>
    </tr>
    <tr>
      <td>These new <font color="blue">regulations</font> may affect  our ability to obtain approvals of <font color="blue">new products</font> for sale in Japan</td>
    </tr>
    <tr>
      <td>Certain of our products, including our dermal <font color="blue">regeneration</font> products, our  <font color="blue">duraplasty</font> products and our nerve repair products, contain material derived from  bovine tissue</td>
    </tr>
    <tr>
      <td>Products that <font color="blue">contain materials derived <font color="blue">from animal sources</font></font>,  including <font color="blue">food as well as pharmaceuticals</font> and <font color="blue">medical devices</font>, are <font color="blue">increasingly</font>  subject to scrutiny in the press and by <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory  </font><font color="blue">authorities</font> are <font color="blue">concerned about</font> the potential for the <font color="blue">transmission</font> of disease  <font color="blue">from animals</font> to <font color="blue">humans via</font> those materials</td>
    </tr>
    <tr>
      <td>This <font color="blue">public scrutiny</font> has been  <font color="blue"><font color="blue">particularly</font> acute</font> in <font color="blue">Japan and Western Europe </font>with respect to <font color="blue">products derived</font>  <font color="blue">from animal sources</font>, because of concern that <font color="blue">materials infected with</font> the agent  that causes bovine spongiform encephalopathy, otherwise known as BSE or mad cow  disease, may, if ingested or implanted, cause a variant of the human  Creutzfeldt-Jakob Disease, an ultimately fatal disease with no known cure</td>
    </tr>
    <tr>
      <td>Recent cases of BSE in cattle discovered in Canada and the <font color="blue"><font color="blue">United States</font> </font>have  <font color="blue">increased awareness</font> of the issue in North America</td>
    </tr>
    <tr>
      <td>In particular, the <font color="blue">collagen used</font> in the products that <font color="blue">Integra  </font><font color="blue">manufacture</font>s is <font color="blue">derived only from</font> the <font color="blue">deep <font color="blue">flexor tendon</font></font> of cattle less than 24  months old from New Zealand, a country that has never had a case of BSE, or the  <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">collagen used</font> in a product that we sell, but do not  <font color="blue">manufacture</font>, is <font color="blue">derived from <font color="blue">bovine pericardium</font></font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">also qualifying sources</font>  of <font color="blue">collagen from</font> other countries that are considered BSE-free</td>
    </tr>
    <tr>
      <td>The World Health  Organization <font color="blue">classifies different types</font> of <font color="blue">cattle tissue</font> for <font color="blue">relative risk</font> of  BSE <font color="blue">transmission</font></td>
    </tr>
    <tr>
      <td>Deep <font color="blue">flexor tendon</font> and <font color="blue">bovine pericardium</font> are in the lowest  <font color="blue">risk categories</font> for BSE <font color="blue">transmission</font> (the same category as milk, for example),  and are therefore considered to have a <font color="blue">negligible risk</font> of containing the agent  that causes BSE (an <font color="blue">improperly</font> folded protein known as a prion)</td>
    </tr>
    <tr>
      <td>Nevertheless,  products that contain materials derived <font color="blue">from animals</font>, including our products,  may become subject to <font color="blue">additional</font> regulation, or even be banned in certain  countries, because of concern over the potential for prion <font color="blue">transmission</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">new regulation</font>, or a ban of our products, could have a material  adverse effect on our current business or our ability to expand our business</td>
    </tr>
    <tr>
      <td>In addition, we have <font color="blue">been notified</font> that Japan has issued new <font color="blue">regulations</font>  regarding <font color="blue">medical devices</font> that <font color="blue">contain tissue</font> of <font color="blue">animal origin</font></td>
    </tr>
    <tr>
      <td>Among other  <font color="blue">regulations</font>, Japan may require that the <font color="blue">tendon used</font> in the <font color="blue">manufacture</font> of  <font color="blue">medical devices</font> sold in Japan originate in a country that has never had a case                                           13  <PAGE>    of BSE Currently, we purchase our <font color="blue">tendon from</font> the <font color="blue"><font color="blue">United States</font> </font>and New  Zealand</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot continue</font> to use or qualify a source of <font color="blue">tendon from</font> New  Zealand or another country that has never had a case of BSE, we will not be  permitted to sell our <font color="blue">collagen hemostatic agents</font> and products for <font color="blue">oral surgery</font>  in Japan</td>
    </tr>
    <tr>
      <td>We do not <font color="blue">currently sell</font> our dural or <font color="blue">skin repair products</font> in Japan</td>
    </tr>
    <tr>
      <td>We cannot be certain that our <font color="blue">current products</font> or any other products that we may  develop or <font color="blue">market will</font> achieve or maintain <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Certain of the  medical <font color="blue">indications</font> that can be <font color="blue">treated by</font> our devices can also be <font color="blue">treated by</font>  other <font color="blue">medical devices</font> or <font color="blue">by medical practices</font> that do not include a device</td>
    </tr>
    <tr>
      <td>The  <font color="blue"><font color="blue">medical community</font> widely accepts</font> many <font color="blue">alternative</font> <font color="blue">treatments</font>, and certain of  these other <font color="blue">treatments</font> have a <font color="blue">long history</font> of use</td>
    </tr>
    <tr>
      <td>For example, the use of  <font color="blue">autograft tissue</font> is a well-established means for repairing the dermis, and it  competes for <font color="blue">acceptance</font> in the <font color="blue">market with</font> the INTEGRA(R) Dermal Regeneration  Template</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">acceptance</font> of our Newdeal products, which previously  were distributed by <font color="blue">third parties</font>, faces similar <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that our devices and <font color="blue">procedures will</font> be able to replace  those established <font color="blue">treatments</font> or that <font color="blue">either physicians</font> or the <font color="blue">medical community</font>  in <font color="blue">general will accept</font> and utilize our devices or any other <font color="blue">medical products</font>  that we may develop</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">future success depends</font>, in part, on our ability to develop  <font color="blue">additional</font> products</td>
    </tr>
    <tr>
      <td>Even if we determine that a <font color="blue">product candidate</font> has medical  benefits, the cost of <font color="blue">commercializing</font> that <font color="blue">product candidate</font> may be too high to  justify <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may develop products that are more <font color="blue">effective</font>,  achieve more favorable <font color="blue">reimbursement</font> status from third-party payors, cost less  or are ready for <font color="blue">commercial introduction</font> before our products</td>
    </tr>
    <tr>
      <td>If we are unable  to develop <font color="blue">additional</font> commercially viable products, our <font color="blue">future prospects could</font>  be <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of our <font color="blue">products depends on</font> many factors, including our ability  to <font color="blue">convince prospective collaborators</font> and customers that our <font color="blue">technology</font> is an  attractive <font color="blue">alternative</font> to other <font color="blue">technologies</font>, to <font color="blue">manufacture</font> products in  <font color="blue">sufficient quantities</font> and at acceptable costs, and to supply and service  <font color="blue">sufficient quantities</font> of our <font color="blue">products directly</font> or through our <font color="blue">distribution</font>  alliances</td>
    </tr>
    <tr>
      <td>In addition, unfavorable <font color="blue">reimbursement</font> <font color="blue">methodologies</font> of third-party  payors <font color="blue">could harm</font> <font color="blue">acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>The industry is subject to rapid  and <font color="blue">continuous</font> change arising from, among other things, consolidation and  <font color="blue">technological improvements</font></td>
    </tr>
    <tr>
      <td>One or more of these factors may vary <font color="blue">unpredictably</font>,  <font color="blue">which could</font> have a material adverse effect on our <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>We may  not be able to adjust our contemplated plan of <font color="blue">development</font> to meet changing  <font color="blue">market demands</font></td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue"><font color="blue">effective</font>ly</font> depends in part, on our ability to maintain  the <font color="blue">proprietary</font> nature of our <font color="blue">technologies</font> and <font color="blue">manufacturing</font> processes, which  includes the ability to obtain, protect and <font color="blue">enforce patents on</font> our <font color="blue">technology</font>  and to protect our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We own or have <font color="blue">licensed patents</font> that cover  aspects of some of our <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>However, you should not rely on our  patents to <font color="blue">provide us with</font> any <font color="blue">significant</font> <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>Others may  challenge our patents and, as a result, our <font color="blue">patents could</font> be narrowed,  invalidated or rendered unenforceable</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may develop products similar  to ours that our patents do not cover</td>
    </tr>
    <tr>
      <td>In addition, our current and future  patent <font color="blue">application</font>s may not result in the issuance of patents in the United  States or <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>Further, there is a substantial backlog of patent  <font color="blue">application</font>s at the US Patent and Trademark Office, and the approval or  rejection of patent <font color="blue">application</font>s usually takes <font color="blue">approximately two years</font></td>
    </tr>
    <tr>
      <td>Trade  secrets are <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">others will</font> not  <font color="blue">independently</font> develop substantially equivalent <font color="blue">proprietary</font> information and                                           14  <PAGE>    <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font> to our <font color="blue">trade secrets</font>, that our <font color="blue">trade secrets</font>  will not be disclosed or that we can <font color="blue"><font color="blue">effective</font>ly</font> protect our rights to  unpatented <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>In an effort to protect our <font color="blue">trade secrets</font>, we require our employees, <font color="blue">consultants</font>  and advisors to execute <font color="blue">proprietary</font> information and invention <font color="blue">assignment</font>  <font color="blue">agreements</font> upon <font color="blue">commencement</font> of <font color="blue">employment</font> or consulting <font color="blue">relationships</font> with us</td>
    </tr>
    <tr>
      <td>These <font color="blue">agreements</font> provide that, except in <font color="blue">specified circumstances</font>, all  <font color="blue">confidential</font> information developed or made known to the individual during the  course of their <font color="blue">relationship with us must</font> be kept <font color="blue">confidential</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font>  you, however, that these <font color="blue">agreements</font> will provide meaningful protection for our  <font color="blue">trade secrets</font> or other <font color="blue">proprietary</font> information in the event of the <font color="blue">unauthorized</font>  use or <font color="blue">disclosure</font> of <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>We may be sued for infringing the <font color="blue">intellectual property rights</font> of others</td>
    </tr>
    <tr>
      <td>In  addition, we may find it <font color="blue">necessary</font>, if threatened, to initiate a <font color="blue">lawsuit seeking</font>  a <font color="blue">declaration from</font> a court that we do not infringe the <font color="blue">proprietary</font> rights of  others or that their rights are invalid or unenforceable</td>
    </tr>
    <tr>
      <td>If we do not prevail  in any <font color="blue">litigation</font>, in addition to any damages we might have to pay, we would be  required to stop the <font color="blue">infringing activity</font> or obtain a license for the <font color="blue">proprietary</font>  <font color="blue">rights involved</font></td>
    </tr>
    <tr>
      <td>Any required <font color="blue">license may</font> be unavailable to us on acceptable  terms, or at all</td>
    </tr>
    <tr>
      <td>In addition, some licenses may be <font color="blue">nonexclusive</font> and allow our  <font color="blue">competitors</font> to access the same <font color="blue">technology</font> we license</td>
    </tr>
    <tr>
      <td>If we fail to obtain a  required license or are unable to design our product so as not to <font color="blue">infringe on</font>  the <font color="blue">proprietary</font> rights of others, we may be unable to sell some of our products,  <font color="blue">which could</font> have a material adverse effect on our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>To protect or enforce our <font color="blue">intellectual property rights</font>, we may have to initiate  legal proceedings, such as infringement suits or <font color="blue">interference proceedings</font>,  <font color="blue">against <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>For example, in <font color="blue">December </font>2005 our Newdeal <font color="blue">subsidiary sued</font>  Wright Medical Group, Inc</td>
    </tr>
    <tr>
      <td>and Wright Medicalapstas French subsidiary alleging that  certain <font color="blue">products with</font>in Wright Medicalapstas  &amp;quote <font color="blue">Charlotte System </font>&amp;quote  of foot and ankle  <font color="blue">products infringe upon</font> Newdealapstas foot-and-ankle system</td>
    </tr>
    <tr>
      <td>In addition, we may have  to <font color="blue">institute proceedings</font> regarding our <font color="blue">competitors</font> &amp;apos  <font color="blue">promotional practices</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>is costly, and, even if we prevail, the cost of that <font color="blue">litigation</font> could  affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">litigation</font> is time consuming and could  <font color="blue">divert <font color="blue">management</font> attention</font> and <font color="blue">resources away from</font> our business</td>
    </tr>
    <tr>
      <td>We may also  provoke these <font color="blue">third parties</font> to assert claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Outside vendors, some of whom are sole-source suppliers, provide key <font color="blue">components</font>  and <font color="blue">raw materials used</font> in the <font color="blue">manufacture</font> of our products</td>
    </tr>
    <tr>
      <td>Although we believe  that <font color="blue">alternative</font> sources for many of these <font color="blue">components</font> and raw materials are  available, any supply interruption in a limited or sole source component or raw  material <font color="blue">could harm</font> our ability to <font color="blue">manufacture</font> our <font color="blue">products until</font> a new source  of supply is identified and qualified</td>
    </tr>
    <tr>
      <td>In addition, an <font color="blue">uncorrected defect</font> or  supplierapstas variation in a component or raw material, <font color="blue">either unknown</font> to us or  <font color="blue">incompatible with</font> our <font color="blue">manufacturing</font> process, <font color="blue">could harm</font> our ability to  <font color="blue">manufacture</font> products</td>
    </tr>
    <tr>
      <td>We may not be able to find a sufficient <font color="blue">alternative</font>  supplier in a reasonable time period, or <font color="blue">on commercially reasonable terms</font>, if at  all, and our ability to produce and supply our <font color="blue">products could</font> be impaired</td>
    </tr>
    <tr>
      <td>We  believe that these factors are <font color="blue">most likely</font> to affect the <font color="blue">following products</font> that  we <font color="blue">manufacture</font>:          o  our collagen-based products, such as the INTEGRA(R) Dermal Regeneration           Template and wound dressing products, the DuraGen(R) family of           products, and our Absorbable Collagen Sponges;        o  our products made from silicone, such as our <font color="blue">neurosurgical shunts</font> and           <font color="blue">drainage systems</font> and <font color="blue">hemodynamic shunts</font>; and        o  <font color="blue">products which use</font> many <font color="blue">different electronic parts from numerous</font>           suppliers, such as our <font color="blue">intracranial monitors</font> and <font color="blue">catheters</font></td>
    </tr>
    <tr>
      <td>If we were <font color="blue">suddenly unable</font> to <font color="blue">purchase products from one</font> or more of these  companies, we would need a <font color="blue">significant</font> period of time to qualify a <font color="blue">replacement</font>,  and the production of any affected <font color="blue">products could</font> be disrupted</td>
    </tr>
    <tr>
      <td>While it is our  policy to maintain <font color="blue">sufficient inventory</font> of <font color="blue">components</font> so that our production                                           15  <PAGE>    will not be <font color="blue">significant</font>ly disrupted even if a particular component or material  is not available for a period of time, we <font color="blue">remain at risk</font> that we will not be  able to qualify new <font color="blue">components</font> or materials quickly enough to prevent a  <font color="blue">disruption</font> if one or more of our <font color="blue">suppliers ceases production</font> of important  <font color="blue">components</font> or materials</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> our products in a limited number of <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Damage to our  <font color="blue">manufacturing</font>, <font color="blue">development</font> or research <font color="blue">facilities</font> due to fire, natural disaster,  power loss, <font color="blue">communications</font> failure, <font color="blue">unauthorized</font> entry or other <font color="blue">events could</font>  cause us to cease <font color="blue">development</font> and <font color="blue">manufacturing</font> of some or all of our products</td>
    </tr>
    <tr>
      <td>In particular, our San Diego, California <font color="blue">facility</font> that <font color="blue">manufacture</font>s our  Camino(R), Ventrix(R) and LICOX(R) catheter <font color="blue">product lines</font> is <font color="blue">as susceptible</font> to  earthquake damage, wildfire damage and <font color="blue">power losses from electrical shortages as</font>  are other <font color="blue">businesses</font> in the <font color="blue">Southern California </font>area</td>
    </tr>
    <tr>
      <td>Our Anasco, Puerto Rico  plant, where we <font color="blue">manufacture</font> collagen, silicone and our <font color="blue"><font color="blue">private label</font> products</font>,  is vulnerable to hurricane, storm and wind damage</td>
    </tr>
    <tr>
      <td>Although we maintain property  damage and business <font color="blue">interruption <font color="blue">insurance coverage</font> on</font> these <font color="blue">facilities</font>, our  <font color="blue">insurance might</font> not cover all <font color="blue">losses under such circumstances</font> and we may not be  able to renew or obtain <font color="blue">such insurance</font> in the future on acceptable terms with  <font color="blue">adequate coverage</font> or <font color="blue">at reasonable costs</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">began implementing</font> an enterprise business system in 2004, which  we intend to use in all of our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>This system, the hosting and  maintenance of which we outsource, replaces several systems on which we  <font color="blue">previously relied</font> and will be implemented in <font color="blue">several stages</font></td>
    </tr>
    <tr>
      <td>We have outsourced  our product <font color="blue">distribution</font> function in the <font color="blue"><font color="blue">United States</font> </font>and in the <font color="blue">fourth quarter</font>  of 2005 began to outsource our European product <font color="blue">distribution</font> function</td>
    </tr>
    <tr>
      <td>A delay  or other <font color="blue">problem with</font> the system or in our <font color="blue">implementation schedule</font> for any of  these <font color="blue"><font color="blue">initiatives</font> could</font> have a material adverse effect on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We generate <font color="blue">significant</font> revenues outside the <font color="blue"><font color="blue">United States</font> </font>in euros, <font color="blue">British  </font>pounds and in US dollar-denominated transactions conducted <font color="blue">with customers</font> who  <font color="blue">generate revenue</font> in currencies other than the US dollar</td>
    </tr>
    <tr>
      <td>For those foreign  customers who purchase our products in US dollars, currency <font color="blue">fluctuations</font>  between the US dollar and the currencies in which those customers do business  may have an <font color="blue">impact on</font> the demand for our products in <font color="blue">foreign countries</font> where the  US dollar has increased in <font color="blue">value compared</font> to the <font color="blue">local currency</font></td>
    </tr>
    <tr>
      <td>Because we have <font color="blue">operations</font> based in Europe and we <font color="blue">generate revenue</font>s and incur  operating expenses in euros <font color="blue">and British </font>pounds, we experience <font color="blue">currency exchange</font>  <font color="blue">risk with respect</font> to those foreign currency-denominated revenues and expenses</td>
    </tr>
    <tr>
      <td>In 2004 and 2005, the cost of products we <font color="blue">manufacture</font>d in our <font color="blue">European  </font><font color="blue">facilities</font> or purchased in foreign currencies exceeded our foreign  currency-denominated revenues</td>
    </tr>
    <tr>
      <td>Accordingly, a weakening of the <font color="blue">dollar against</font> the euro <font color="blue">and British </font><font color="blue">pound could</font>  <font color="blue">negatively affect future</font> gross margins and operating margins</td>
    </tr>
    <tr>
      <td>Currently, we do not <font color="blue">use derivative financial <font color="blue">instruments</font></font> to manage operating  <font color="blue">foreign currency risk</font></td>
    </tr>
    <tr>
      <td>If we  believe that this <font color="blue">potential impact presents</font> a <font color="blue">significant</font> risk to our business,  we may <font color="blue">enter into</font> derivative financial <font color="blue">instruments</font> to mitigate this risk</td>
    </tr>
    <tr>
      <td>In general, we <font color="blue">cannot predict</font> the <font color="blue">consolidated effects</font> of <font color="blue">exchange rate</font>  <font color="blue">fluctuations</font> upon our future operating results because of the number of  <font color="blue">currencies involved</font>, the <font color="blue">variability</font> of <font color="blue">currency exposure</font> and the potential  <font color="blue">volatility</font> of <font color="blue">currency exchange</font> rates</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> <font color="blue">operations</font> subject us to customs and import-export laws</td>
    </tr>
    <tr>
      <td>These  <font color="blue">laws restrict</font>, and in some <font color="blue">cases prohibit</font>, <font color="blue"><font color="blue">United States</font> </font><font color="blue">companies from directly</font>  or <font color="blue">indirectly selling</font> goods, <font color="blue">technology</font> or services to people or entities in  <font color="blue">certain countries</font></td>
    </tr>
    <tr>
      <td>Our sales to <font color="blue">foreign markets also may</font> be <font color="blue">affected by local economic conditions</font>,  legal, <font color="blue">regulatory</font> or <font color="blue">political considerations</font>, the <font color="blue"><font color="blue">effective</font>ness</font> of our sales  <font color="blue">representatives</font> and distributors, local <font color="blue">competition</font> and changes in <font color="blue">local medical</font>                                           16  <PAGE>    practice</td>
    </tr>
    <tr>
      <td><font color="blue">Relationships </font><font color="blue">with customers</font> and <font color="blue">effective</font> terms of <font color="blue">sale frequently</font>  vary by country, often with longer-term receivables than are typical in the  <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Trends toward managed care, health care cost containment and other changes in  <font color="blue">government</font> and private sector <font color="blue">initiatives</font> in the <font color="blue"><font color="blue">United States</font> </font>and other  countries in which we do business are <font color="blue">placing increased emphasis on</font> the delivery  of more cost-<font color="blue">effective</font> medical therapies that <font color="blue">could <font color="blue">adversely affect</font></font> the sale  and/or the prices of our products</td>
    </tr>
    <tr>
      <td>For example:          o  major third-party payors of hospital services and <font color="blue">hospital outpatient</font>           services, including Medicare, Medicaid and private health care           insurers, annually revise their payment <font color="blue">methodologies</font>, which can result           in stricter standards for <font color="blue">reimbursement</font> of hospital charges for certain           medical procedures;        o  Medicare, Medicaid and private health care insurer cutbacks could           create downward price pressure on our products;        o  potential <font color="blue">legislative</font> proposals have been considered that would result           in major reforms <font color="blue">in the US </font><font color="blue">health care system</font> that could have an           adverse effect on our business;        o  there has been a consolidation among health care <font color="blue">facilities</font> and           purchasers of <font color="blue">medical devices</font> in the <font color="blue"><font color="blue">United States</font> </font>who prefer to limit           the number of suppliers from whom they purchase <font color="blue">medical products</font>, and           these entities may decide to stop purchasing our products or demand           discounts on our prices;        o  we are party to contracts with group purchasing <font color="blue">organizations</font>, which           negotiate pricing for many member hospitals, that require us to           discount our prices for certain of our products and limit our ability           to raise prices for certain of our products, <font color="blue">particularly</font> surgical           <font color="blue">instruments</font>;        o  there is economic pressure to contain health care costs in domestic and           <font color="blue">international</font> markets;        o  there are proposed and existing laws, <font color="blue">regulations</font> and industry policies           in domestic and <font color="blue">international</font> markets regulating the sales and           <font color="blue">marketing practices</font> and the pricing and <font color="blue">profitability</font> of companies in           the <font color="blue">health care industry</font>;        o  <font color="blue">proposed laws</font> or <font color="blue">regulations</font> that <font color="blue">will permit hospitals</font> to provide           <font color="blue">financial incentives</font> to doctors for reducing hospital costs (known as           <font color="blue">gainsharing</font>) and to award physician efficiency (known as physician           profiling) could reduce prices; and        o  there have been <font color="blue">initiatives</font> by third-party payors to challenge the           <font color="blue">prices charged</font> for <font color="blue">medical products</font> that <font color="blue">could affect</font> our ability to           <font color="blue">sell products on</font> a <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td>Both the pressures to reduce prices for our products in response to these trends  and the decrease in the size of the <font color="blue">market as</font> a result of these <font color="blue">trends could</font>  <font color="blue">adversely affect</font> our levels of revenues and <font color="blue">profitability</font> of sales</td>
    </tr>
    <tr>
      <td>Regulatory Oversight Of The Medical Device Industry Might Affect The Manner In  Which We May Sell Medical Devices    There are laws and <font color="blue">regulations</font> that regulate the means <font color="blue">by which companies</font> in the  <font color="blue">health care industry</font> may market their products to <font color="blue">health care professionals</font> and  <font color="blue">may compete by discounting</font> the prices of their products</td>
    </tr>
    <tr>
      <td>Although we exercise  care in structuring our sales and <font color="blue">marketing practices</font> and customer discount  <font color="blue">arrangements</font> to <font color="blue">comply with</font> those laws and <font color="blue">regulations</font>, we <font color="blue">cannot assure</font> you  that:          o  <font color="blue">government</font> officials charged with responsibility for enforcing those           laws will not assert that our sales and <font color="blue">marketing practices</font> or customer           discount <font color="blue">arrangements</font> are in violation of those laws or <font color="blue">regulations</font>; or        o  <font color="blue">government</font> regulators or <font color="blue">courts will interpret</font> those laws or           <font color="blue">regulations</font> in a <font color="blue">manner consistent with</font> our <font color="blue">interpretation</font></td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2004, ADVAMED, the principal US <font color="blue">trade association</font> for the medical  device industry, put in place a model  &amp;quote code of conduct &amp;quote  that sets forth  <font color="blue">standards by which</font> its <font color="blue">members should abide</font> in the promotion of their products</td>
    </tr>
    <tr>
      <td>We have in place policies and procedures for compliance that we believe are at                                           17  <PAGE>    <font color="blue">least as stringent as</font> those set forth in the ADVAMED Code, and we provide  routine training to our sales and marketing personnel on our policies regarding  sales and <font color="blue">marketing practices</font></td>
    </tr>
    <tr>
      <td>Nevertheless, the sales and <font color="blue">marketing practices</font>  of our industry has been the subject of increased scrutiny from <font color="blue">government</font>  agencies, and we believe that this trend will continue</td>
    </tr>
    <tr>
      <td>Our <font color="blue">private label</font> business depends in part on our <font color="blue">entering into</font> and maintaining  <font color="blue">collaborative</font> or alliance <font color="blue">agreements</font> with <font color="blue">third parties</font> concerning product  marketing, as well as research and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>Our <font color="blue">most important</font>  alliance is our <font color="blue">agreement with</font> the Wyeth BioPharma division of Wyeth for the  <font color="blue">development</font> of <font color="blue">collagen matrices</font> to be used in <font color="blue">conjunction with</font> Wyeth  BioPharmaapstas <font color="blue">recombinant bone protein</font>, a protein that stimulates the growth of  bone in humans</td>
    </tr>
    <tr>
      <td>The <font color="blue">third parties</font> with whom we have entered into <font color="blue">agreements</font>  <font color="blue">might terminate</font> these <font color="blue">agreements</font> for a variety of reasons, including developing  other sources for the <font color="blue">product supplied by us</font></td>
    </tr>
    <tr>
      <td><font color="blue">Termination </font>of any of our  <font color="blue">alliances would</font> require us to develop other means to distribute the affected  products and <font color="blue">could <font color="blue">adversely affect</font></font> our <font color="blue">expectations</font> for the growth of private  <font color="blue">label products</font></td>
    </tr>
    <tr>
      <td>We are exposed to <font color="blue">product liability</font> and other claims in the event that our  <font color="blue">technologies</font> or products are alleged to have caused harm</td>
    </tr>
    <tr>
      <td>We may not be able to  obtain insurance for the <font color="blue">potential liability on</font> acceptable <font color="blue">terms with adequate</font>  coverage or <font color="blue">at reasonable costs</font></td>
    </tr>
    <tr>
      <td>Any potential <font color="blue">product liability</font> claims could  exceed the amount of our <font color="blue">insurance coverage</font> or may be <font color="blue">excluded from coverage</font>  under the terms of the policy</td>
    </tr>
    <tr>
      <td>Our insurance may not be <font color="blue">renewed at</font> a cost and  level of <font color="blue">coverage comparable</font> to that then in effect</td>
    </tr>
    <tr>
      <td>Our research, <font color="blue">development</font> and <font color="blue">manufacturing</font> processes involve the <font color="blue">controlled use</font>  of <font color="blue">certain hazardous materials</font></td>
    </tr>
    <tr>
      <td>We are subject to federal, state and <font color="blue">local laws</font>  and <font color="blue">regulations</font> governing the use, <font color="blue">manufacture</font>, storage, handling and disposal  of these materials and <font color="blue">certain waste products</font></td>
    </tr>
    <tr>
      <td>Although we believe that our  <font color="blue">safety procedures</font> for handling and disposing of those materials <font color="blue">comply with</font> the  <font color="blue">standards prescribed by</font> the <font color="blue">applicable laws</font> and <font color="blue">regulations</font>, the risk of  <font color="blue"><font color="blue">accident</font>al contamination</font> or <font color="blue">injury from</font> these <font color="blue">materials cannot</font> be eliminated</td>
    </tr>
    <tr>
      <td>In  the event of such an <font color="blue">accident</font>, we could be held liable for any damages that  result and any related <font color="blue">liability <font color="blue">could exceed</font></font> the limits or <font color="blue">fall outside</font> the  coverage of our insurance and <font color="blue">could exceed</font> our resources</td>
    </tr>
    <tr>
      <td>We may not be able to  maintain <font color="blue">insurance on</font> acceptable terms or at all</td>
    </tr>
    <tr>
      <td><font color="blue">The Loss Of Key Personnel Could Harm Our Business</font></td>
    </tr>
    <tr>
      <td>We believe our <font color="blue">success depends on</font> the <font color="blue">contributions</font> of a number of our key  personnel, including Stuart M Essig, our <font color="blue">President and Chief Executive Officer</font></td>
    </tr>
    <tr>
      <td>If we lose the services of <font color="blue">key personnel</font>, those <font color="blue">losses could materially harm</font> our  business</td>
    </tr>
    <tr>
      <td>We maintain key person life <font color="blue">insurance on</font> Mr</td>
    </tr>
    <tr>
      <td>Essig and two other  members of <font color="blue">management</font></td>
    </tr>
  </tbody>
</table>